Seres Therapeutics (MCRB) Tops Q2 EPS by 277c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.47, $2.77 better than the analyst estimate of ($2.30). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $358 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Santacruz Silver Reports Second Quarter 2026 Financial Results
• Kuya Silver Reports Q2, 2026 Financial Results - Advances Bethania Mine Development and Drilling Program